Guru Fundamental Report for HIMS

Validea's guru fundamental report indicates that HIMS & HERS HEALTH INC (HIMS) scores highly (77%) using their P/B Growth Investor model based on Partha Mohanram's strategy, which seeks low book-to-market stocks with sustained growth characteristics; the model gives HIMS passing grades on book/market ratio, return on assets, cash flow from operations to assets, return on assets variance, and advertising to assets, but it fails on sales variance and research and development to assets.

Analysis

HIMS & HERS HEALTH INC (HIMS), a mid-cap growth stock in the Biotechnology & Drugs industry, has received a 77% rating from Validea's P/B Growth Investor model, a strategy developed by Partha Mohanram designed to identify low book-to-market stocks with characteristics indicative of sustained future growth. While this score approaches the 80% threshold typically signaling strategy interest, it remains below the 90% mark for strong interest. HIMS demonstrates strength in several fundamental areas, passing criteria for its book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, advertising to assets, and capital expenditures to assets. However, the company fails on two notable criteria: sales variance and research and development to assets. The failure on sales variance suggests potential inconsistency in revenue growth, a critical factor for growth stocks, while the low R&D to assets ratio may raise questions about the long-term innovation pipeline, particularly for a company in the biotechnology sector.

Key Decisions for Investors

• Investors should note the generally positive assessment from the Mohanram P/B Growth model, but recognize the 77% score indicates moderate, not strong, alignment, warranting careful consideration of its growth sustainability.
• Further due diligence is crucial to understand the underlying causes for the 'FAIL' ratings on 'SALES VARIANCE' and 'RESEARCH AND DEVELOPMENT TO ASSETS', as these could represent significant headwinds for a growth-oriented biotechnology firm.
• Consider monitoring HIMS for improvements in sales growth consistency and R&D investment levels, as positive developments in these areas could strengthen its profile under this specific quantitative growth strategy and potentially signal enhanced long-term prospects.